Eidos Therapeutics (FRA:6MX) Interest Coverage : 0 (At Loss) (As of Sep. 2020)

Eidos Therapeutics Interest Coverage Chart

Eidos Therapeutics Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Interest Coverage	Get a 7-Day Free Trial											N/A	-	-	-	-

Competitive Comparison of Eidos Therapeutics's Interest Coverage

For the Biotechnology subindustry, Eidos Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eidos Therapeutics's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eidos Therapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Eidos Therapeutics's Interest Coverage falls into.

Eidos Therapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Else if Interest Expense is negative and Operating Income is negative, then

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Eidos Therapeutics's Interest Coverage for the fiscal year that ended in Dec. 2019 is calculated as

Here, for the fiscal year that ended in Dec. 2019, Eidos Therapeutics's Interest Expense was €-0.29 Mil. Its Operating Income was €-36.41 Mil. And its Long-Term Debt & Capital Lease Obligation was €18.63 Mil.

Eidos Therapeutics's Interest Coverage for the quarter that ended in Sep. 2020 is calculated as

Here, for the three months ended in Sep. 2020, Eidos Therapeutics's Interest Expense was €-0.65 Mil. Its Operating Income was €-24.96 Mil. And its Long-Term Debt & Capital Lease Obligation was €17.72 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.

Eidos Therapeutics  (FRA:6MX) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Eidos Therapeutics Interest Coverage Related Terms

Thank you for viewing the detailed overview of Eidos Therapeutics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Eidos Therapeutics (FRA:6MX) Business Description